Two acquisitions — one from a French pharmaceutical giant and another from a 60-year-old Japanese Contract Development and Manufacturing Organization (CDMO) — could transform Gujarat Themis Biosyn (GTBL), a Vapi-based manufacturer of anti-infective pharmaceutical ingredients, into a global pharmaceutical platform.

For more than three decades, Gujarat Themis Biosyn has operated quietly but profitably, generating industry-leading margins and, at its peak, return on equity above 50%.

Now, within just five weeks, GTBL has announced acquisitions worth nearly Rs 3,000 crore, despite having a market cap of less than Rs 4,000 crore when the deals were announced.

This marks a defining moment for the company. If executed successfully, these transactions could fundamentally reshape GTBL’s future. If not, they risk stretching both management bandwidth and the balance sheet.

Let us understand what these deals mean for the business, and whether the numbers support the ambition.

To understand the implications, let’s examine the company’s business model and assess whether the numbers support its ambitions.

Founded in 1981, Gujarat Themis Biosyn has built a strong niche in fermentation-based Active Pharmaceutical Ingredients (API) manufacturing, an area that requires specialised infrastructure, regulatory approvals, and decades of technical expertise.

The company was India’s first commercial producer of Rifampicin and today manufactures key intermediates such as Rifamycin-S and Rifamycin-O, which are used in the production of Rifampicin and Rifaximin. It also produces Lovastatin, a fermentation-derived cholesterol-lowering drug.

In essence, GTBL occupies a critical position in the anti-infective pharmaceutical value chain, supplying products that are essential for the manufacture of some of the world’s most important anti-tuberculosis medicines.

Historically, the business has been highly concentrated but exceptionally efficient.

GTBL supplies its products under long-term take-or-pay agreements to two major pharmaceutical customers. Lupin Limited accounts for approximately 56% of sales, while Optrix Laboratories contributes the remainder. These agreements protect against demand uncertainty while giving customers supply assurance.

The result has been a financial profile rarely seen in a company with less than Rs 200 crore in annual revenue. EBITDA margins have consistently exceeded 40%, PAT margins have remained between 30% and 40% for five consecutive years through FY25, return on equity has stayed above 30%, and the balance sheet entered FY26 virtually debt-free.

In October 2025, GTBL commissioned an expanded fermentation facility in Vapi, increasing capacity from 450 KL to 990 KL, a 120% increase. This alone provides a platform for volume-led growth even before either acquisition is completed.

On April 23, 2026, GTBL signed an asset purchase agreement with Sanofi to acquire a portfolio of 13 branded generic anti-tuberculosis and anti-infective products, along with their marketing authorisations, regulatory dossiers, trademarks, and inventory.

The price: 158 million euros (approximately Rs 1,738 crore) payable in cash at closing, expected by December 2026.

The geography: over 55 countries spanning Europe, the Middle East, and Africa.

What makes the structure particularly interesting is what it does not include: manufacturing facilities and employees.

This is an asset-light acquisition. GTBL is buying the commercial rights, the brand equity, and the regulatory infrastructure, without taking on the operational complexity of running a European manufacturing footprint.

The strategic rationale is straightforward. GTBL currently operates upstream, supplying intermediates and API-stage materials to pharmaceutical companies. This acquisition moves it directly up the value chain, from manufacturing anti-TB drug ingredients to owning the brands consumed by patients.

The real synergy is vertical integration. GTBL already produces Rifamycin-S, a key precursor for Rifampicin. By acquiring branded anti-infective products, it gains a downstream presence in the same therapeutic segment, with the potential to integrate its own APIs into these brands and build a highly differentiated end-to-end TB platform.

If the Sanofi acquisition is about moving downstream into branded generics, the MicroBiopharm Japan acquisition is about moving into an entirely different business model.

On May 22, 2026, GTBL announced the acquisition of 100% equity in MicroBiopharm Japan Co., Ltd. (MBJ) from funds managed by T Capital Partners, a Japan-based private equity firm. The transaction is valued at approximately JPY 21.5 billion, or roughly Rs 1,300 crore, to be executed through Themis Biosyn Japan Limited, a wholly-owned subsidiary incorporated in Japan on May 19, 2026.

MicroBiopharm Japan is not a new entrant. It has over six decades of experience in microbial fermentation, pharmaceutical research, and specialty chemical manufacturing. But what makes it strategically compelling for GTBL is not its history, it is its capabilities.

MBJ generated an estimated JPY 9.5 billion (~Rs 570 crore) in FY26 revenue, with ~40% coming from international markets.

More than half of its revenue is driven by CDMO and contract services, providing recurring and sticky customer relationships.

More importantly, MBJ brings capabilities that GTBL lacks, but the industry increasingly needs. Its expertise in plasmid DNA manufacturing, a key bottleneck for gene therapies and mRNA vaccines, and ADC conjugation (Antibody-Drug Conjugate) for next-generation oncology drugs positions it at the forefront of advanced biologics manufacturing.

This acquisition is less about buying a fermentation company and more about acquiring a platform spanning precision biology, oncology, and next-generation drug manufacturing. At ~2.3x revenue, the valuation appears attractive relative to listed CDMO peers that often trade at 4-8x sales.

Execution risks remain, including Japanese regulatory approvals and cross-border integration challenges. However, the strategic fit is compelling: GTBL contributes cost-efficient fermentation manufacturing, while MBJ adds advanced technologies, global pharma relationships, and cutting-edge capabilities. Together, they create a platform that neither could build as effectively on its own.

GTBL is heading into these acquisitions with healthy financials. FY26 full-year revenue came in at approximately Rs 165.8 crore, up around 10% year on year. The audited PAT for FY26 was Rs 46.7 crore, a modest decline from FY25 as expanded capacity brought higher depreciation and operating expenses ahead of revenue contribution. EBITDA margins remained strong, above 40%, in Q4 FY26.

The balance sheet, critically, was near debt-free entering this phase of expansion. That is the foundation upon which these deals are being built.

Now consider the pro-forma picture once both acquisitions close, likely by the end of 2026.

If these numbers hold, GTBL’s revenue base could expand from under Rs 200 crore to over Rs 1,300 crore within a year.

However, revenue growth alone does not create value. The Sanofi portfolio brings established brands and global reach but also requires continued investment in sales, market access, and regulatory compliance. MBJ adds attractive CDMO capabilities and advanced technologies, though integration risks remain.

The acquisition price of Rs 3,038 crore is what makes this deal interesting. To fund it, the company is taking on a combination of debt and equity, marking a significant shift for a business that has traditionally operated with little financial leverage. The post-acquisition balance sheet will be very different from what investors are accustomed to.

The key question is whether management can translate this bold strategic move into strong cash flows and sustainable returns.

Three structural tailwinds could make GTBL’s post-acquisition scale sustainable rather than merely acquired.

First, tuberculosis remains one of the world’s deadliest infectious diseases, while investment in TB therapies has lagged. As global funding and treatment programmes expand, GTBL now owns established anti-TB brands across 55 markets, positioning it to benefit from long-term demand.

Second, global pharma’s shift away from China is accelerating India’s emergence as a CDMO hub. GTBL’s fermentation expertise, combined with MBJ’s advanced technologies, creates a differentiated platform blending Indian cost competitiveness with Japanese manufacturing capabilities.

Third, MBJ provides exposure to some of the fastest-growing areas in pharma. Its capabilities in ADC conjugation and plasmid DNA manufacturing place GTBL in high-growth segments such as oncology, gene therapy, and mRNA, where qualified manufacturing capacity remains scarce.

Valuation: Ambition is priced in, execution is not

On a standalone basis, GTBL is expensive.

FY26 revenue stood at Rs 166 crore and EBITDA at Rs 76 crore, implying a current EV/EBITDA multiple of roughly 55x. The market is clearly not valuing the company based on its existing fermentation business. Instead, investors are underwriting the successful completion and integration of the Sanofi and MicroBiopharm Japan acquisitions.

If both transactions close, GTBL’s revenue base could expand to more than Rs 1,300 crore, transforming it from a niche fermentation player into a global platform spanning branded anti-infectives, CDMO services, and advanced biologics manufacturing. The valuation debate, therefore, shifts from standalone earnings to the earning power of the combined entity.

Assuming the combined business can sustain EBITDA margins in the 20-25% range over time, EBITDA could potentially reach Rs 260-325 crore. Under that framework, the implied forward EV/EBITDA falls dramatically from current standalone levels and begins to look far more reasonable.

The opportunity is obvious. So is the risk.

GTBL must integrate a branded portfolio across 55+ countries, absorb a technologically advanced Japanese CDMO, manage a more leveraged balance sheet, and execute without disrupting its core business.

Very few Indian pharma companies have attempted a transformation of this magnitude. The upside could be significant, but the valuation leaves little room for execution missteps.

The main risk is execution. GTBL is making two huge acquisitions at once: a global brand portfolio and a Japanese platform. Managing both will test the company’s leadership and discipline like never before.

Debt is another concern. The Rs 3,000 crore cost is far higher than the current business’s earnings. Financing this through debt and equity means a much heavier financial burden than GTBL has handled in the past.

Regulatory hurdles also exist. The deals require approvals in Japan and the transfer of licenses across 55 countries. Any delays could stall growth and value creation.

In short, while the strategy is strong, success depends entirely on how well GTBL integrates these businesses and manages its new debt.

Note: We have relied on data from http://www.Screener.in and http://www.tijorifinance.com throughout this article. Only in cases where the data was not available, have we used an alternate, but widely used and accepted source of information.

Rahul Rao has helped conduct financial literacy programmes for over 1,50,000 investors. He has also worked at an AIF, focusing on small and mid-cap opportunities.

Disclosure: The writer or his dependents do not hold shares in the securities/stocks/bonds discussed in the article.

The website managers, its employee(s), and contributors/writers/authors of articles have or may have an outstanding buy or sell position or holding in the securities, options on securities or other related investments of issuers and/or companies discussed therein. The content of the articles and the interpretation of data are solely the personal views of the contributors/writers/authors. Investors must make their own investment decisions based on their specific objectives, resources and only after consulting such independent advisors as may be necessary.